Market Overview

BMO Capital Upgrades Halozyme Therapeutics, Inc. to Outperform, Raises to $12.00

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS

Latest Ratings for HALO

DateFirmActionFromTo
Feb 2016Canaccord GenuityInitiates Coverage onBuy
Nov 2015CitigroupInitiates Coverage onBuy
Sep 2015BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for HALO
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings

 

Related Articles (HALO)

Get Benzinga's Newsletters